Alvotech Warrant

NASDAQ:ALVOW USA
Market Cap
$3.07K
Market Cap Rank
#22902 Global
#8049 in USA
Share Price
$0.33
Change (1 day)
+10.00%
52-Week Range
$0.16 - $2.90
All Time High
$5.80
About

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more

Alvotech Warrant (ALVOW) - Net Assets

Latest net assets as of September 2025: $-176.76 Million USD

Based on the latest financial reports, Alvotech Warrant (ALVOW) has net assets worth $-176.76 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.41 Billion) and total liabilities ($1.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-176.76 Million
% of Total Assets -12.54%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

Alvotech Warrant - Net Assets Trend (2020–2024)

This chart illustrates how Alvotech Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Alvotech Warrant (2020–2024)

The table below shows the annual net assets of Alvotech Warrant from 2020 to 2024.

Year Net Assets Change
2024-12-31 $-412.77 Million +55.73%
2023-12-31 $-932.49 Million -65.21%
2022-12-31 $-564.42 Million -316.20%
2021-12-31 $-135.61 Million +84.36%
2020-12-31 $-867.24 Million --

Equity Component Analysis

This analysis shows how different components contribute to Alvotech Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 139867900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $2.83 Million %
Other Comprehensive Income $15.05 Million %
Other Components $2.01 Billion %
Total Equity $-412.77 Million 100.00%

Alvotech Warrant Competitors by Market Cap

The table below lists competitors of Alvotech Warrant ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Alvotech Warrant's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -932,493,000 to -412,771,000, a change of 519,722,000.
  • Net loss of 231,864,000 reduced equity.
  • New share issuances of 150,451,000 increased equity.
  • Other comprehensive income decreased equity by 26,329,000.
  • Other factors increased equity by 627,464,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-231.86 Million -56.17%
Share Issuances $150.45 Million +36.45%
Other Comprehensive Income $-26.33 Million -6.38%
Other Changes $627.46 Million +152.01%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Alvotech Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-12-31 $-27.75 $0.33 x
2021-12-31 $-4.34 $0.33 x
2022-12-31 $-2.85 $0.33 x
2023-12-31 $-4.10 $0.33 x
2024-12-31 $-1.54 $0.33 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Alvotech Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -47.35%
  • • Asset Turnover: 0.40x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2020 0.00% -255.26% 0.14x 0.00x $-83.32 Million
2021 0.00% -276.04% 0.06x 0.00x $-87.94 Million
2022 0.00% -618.55% 0.10x 0.00x $-457.14 Million
2023 0.00% -603.42% 0.10x 0.00x $-458.48 Million
2024 0.00% -47.35% 0.40x 0.00x $-190.59 Million

Industry Comparison

This section compares Alvotech Warrant's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Alvotech Warrant (ALVOW) $-176.76 Million 0.00% N/A $35.01 Million
Abcam plc (ABCZF) $726.90 Million -1.17% 0.45x $5.00 Billion
Able View Global Inc. Warrant (ABLVW) $11.42 Million 85.41% 3.81x $277.93K
Above Food Ingredients Inc. Warrants (ABVEW) $199.86 Million -2.89% 0.00x $6.25 Million
Adamas Trust, Inc. (ADAMG) $2.43 Billion 7.94% 1.33x $2.09 Billion
ADS-TEC ENERGY PLC Warrant (ADSEW) $33.92 Million -162.39% 2.67x $10.06 Million
Alliance Entertainment Holding Corporation Warrants (AENTW) $52.92 Million 10.13% 4.23x $2.29 Million
Forafric Global PLC Warrants (AFRIW) $5.32 Million -457.58% 45.29x $2.67 Million
Centurion Acquisition Corp. Warrant (ALFUW) $282.84 Million 1.97% 0.05x $4.81 Million
Alliance Trust PLC (ALITF) $4.04 Billion 10.04% 0.29x $112.87K